Syndax Pharmaceuticals SNDX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $172.6M+629% | $23.68M— | $0— | $0-100% | ||
| $258.78M+7.1% | $241.65M+48.2% | $163.03M+37.6% | $118.5M+34.3% | ||
| $179.68M+48.6% | $120.88M+80.6% | $66.92M+101% | $33.26M+31.8% | ||
| —— | —— | —— | $33.26M+31.8% | ||
| $445.68M+22.7% | $363.35M+58.0% | $229.95M+51.5% | $151.76M+33.7% | ||
| -$273.08M+19.6% | -$339.67M-47.7% | -$229.95M-51.5% | -$151.76M-679% | ||
| -158.2%+1,276pp | -1,434.4%— | —— | —— | ||
| $6K+700% | -$1K-100% | $208K-93.4% | $3.14M+64.6% | ||
| -$12.34M-159% | $20.91M+1.6% | $20.59M+600% | $2.94M— | ||
| —— | —— | —— | —— | ||
| -$285.42M+10.5% | -$318.76M-52.3% | -$209.36M-40.2% | -$149.34M-699% | ||
| -165.4%+1,181pp | -1,346.1%— | —— | —— | ||
| -$3.29+11.6% | -$3.72-25.3% | -$2.97-21.2% | -$2.45-633% | ||
| -$273.08M+19.6% | -$339.67M-47.7% | -$229.95M-51.5% | -$151.76M-679% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Syndax Pharmaceuticals's revenue?
- Syndax Pharmaceuticals (SNDX) generated $217.4M in revenue over the trailing twelve months, up 397.3% year over year.
- Is Syndax Pharmaceuticals profitable?
- Syndax Pharmaceuticals is not currently profitable: it reported a net loss of $243.2M over the trailing twelve months, a -111.9% net margin.
- What is Syndax Pharmaceuticals's earnings per share?
- Syndax Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.79.
- Where does Syndax Pharmaceuticals's income statement data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
